Sun Pharma gets nod from South African regulator for generic semaglutide injection
Sun Pharmaceutical Industries Ltd. received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection. This medication is intended for adults with inadequately controlled type 2 diabetes mellitus, serving as an adjunct to diet and exercise. The approval marks a significant step for Sun Pharma in expanding its product offerings in the South African market.